BR9910641A - Derivados de benzimidazol como moduladores de ige - Google Patents

Derivados de benzimidazol como moduladores de ige

Info

Publication number
BR9910641A
BR9910641A BR9910641-8A BR9910641A BR9910641A BR 9910641 A BR9910641 A BR 9910641A BR 9910641 A BR9910641 A BR 9910641A BR 9910641 A BR9910641 A BR 9910641A
Authority
BR
Brazil
Prior art keywords
ige
benzimidazole derivatives
modulators
ige modulators
benzimidazole
Prior art date
Application number
BR9910641-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Jagadish Sircar
Mark L Richards
Michael G Campbell
Michael W Major
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22198947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9910641(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of BR9910641A publication Critical patent/BR9910641A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Amplifiers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
BR9910641-8A 1998-05-22 1999-05-21 Derivados de benzimidazol como moduladores de ige BR9910641A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8649498P 1998-05-22 1998-05-22
PCT/US1999/011322 WO1999061019A1 (en) 1998-05-22 1999-05-21 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE

Publications (1)

Publication Number Publication Date
BR9910641A true BR9910641A (pt) 2001-10-02

Family

ID=22198947

Family Applications (3)

Application Number Title Priority Date Filing Date
BR9910642-6A BR9910642A (pt) 1998-05-22 1999-05-21 Análogos de benzimidazol como reguladores descendentes de ige
BR9910641-8A BR9910641A (pt) 1998-05-22 1999-05-21 Derivados de benzimidazol como moduladores de ige
BR9910640-0A BR9910640A (pt) 1998-05-22 1999-05-21 Compostos possuindo propriedades que afetam aige

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9910642-6A BR9910642A (pt) 1998-05-22 1999-05-21 Análogos de benzimidazol como reguladores descendentes de ige

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9910640-0A BR9910640A (pt) 1998-05-22 1999-05-21 Compostos possuindo propriedades que afetam aige

Country Status (22)

Country Link
US (2) US6271390B1 (enExample)
EP (3) EP1077700B1 (enExample)
JP (3) JP2002516276A (enExample)
KR (1) KR100591652B1 (enExample)
CN (4) CN1311675A (enExample)
AT (1) ATE292465T1 (enExample)
AU (3) AU754562B2 (enExample)
BR (3) BR9910642A (enExample)
CA (3) CA2332999A1 (enExample)
CZ (2) CZ20004350A3 (enExample)
DE (1) DE69924607T2 (enExample)
ES (1) ES2241285T3 (enExample)
HU (3) HUP0102550A3 (enExample)
IL (3) IL139827A0 (enExample)
MX (3) MXPA00011422A (enExample)
NO (3) NO20005887L (enExample)
NZ (2) NZ508416A (enExample)
PL (3) PL345560A1 (enExample)
RU (2) RU2236221C2 (enExample)
UA (2) UA67774C2 (enExample)
WO (3) WO1999061019A1 (enExample)
ZA (3) ZA200007754B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
CA2332999A1 (en) * 1998-05-22 1999-12-02 Avanir Pharmaceuticals Compounds having ige affecting properties
JP4748338B2 (ja) * 1998-09-11 2011-08-17 味の素株式会社 ベンゼン誘導体及びその医薬用途
US6270746B1 (en) * 1999-02-17 2001-08-07 David H. Katz Assay for the identification of IgE antibody suppressors
CN1353605A (zh) * 1999-03-26 2002-06-12 欧洲凯尔特股份有限公司 芳基取代的吡唑、咪唑、噁唑、噻唑和吡咯及其应用
JP4609691B2 (ja) 1999-07-01 2011-01-12 味の素株式会社 複素環化合物及びその医薬用途
WO2001016091A1 (en) * 1999-09-01 2001-03-08 Ajinomoto Co.,Inc. Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
JP2004528304A (ja) * 2001-03-12 2004-09-16 アバニール・ファーマシューティカルズ ＩｇＥを調節し、細胞増殖を阻害するためのベンゾイミダゾール化合物
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
NZ530580A (en) * 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1435947B1 (en) 2001-10-19 2007-08-15 Ortho-McNeil Pharmaceutical, Inc. 2-phenyl benzimidazoles and imidazo-¬4,5|-pyridines as cds1/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
US20080081788A1 (en) * 2002-01-14 2008-04-03 Lipps Binie V Diagnosis and treatment for immunoglobulin E (IgE) implicated disorders
US20030157555A1 (en) * 2002-01-14 2003-08-21 Lipps Binie V. Diagnosis and treatment for immunoglobulin E ( IgE) implicated disorders
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2003101927A1 (en) 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
EP1388535A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
ATE536188T1 (de) 2002-08-14 2011-12-15 Macrogenics Inc Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
US20050239844A1 (en) * 2002-11-02 2005-10-27 Kyung-Lim Lee Composition fo preventing secretion of immunoglobulin e-dependent histamine releasing factor
GB2397301A (en) * 2003-01-14 2004-07-21 Novo Pharmaceuticals Ltd De Substituted 1,3,5-triazine derivatives
DE602004006852D1 (de) 2003-04-17 2007-07-19 Janssen Pharmaceutica Nv 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5ü-pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs
AU2004263190A1 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
UY28758A1 (es) 2004-02-20 2005-09-30 Boehringer Ingelheim Int Inhibidores de polimerasa viral
SG137850A1 (en) * 2004-05-12 2007-12-28 Proteotech Inc Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
EP1824832B1 (en) 2004-06-30 2011-04-27 Janssen Pharmaceutica NV Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
ATE533485T1 (de) † 2005-10-31 2011-12-15 Merck Sharp & Dohme Cetp-inhibitoren
EP1790345A1 (en) * 2005-11-02 2007-05-30 Esbatech AG Triazin beta-secretase inhibitors
CN101395147B (zh) * 2005-12-28 2013-05-29 弗特克斯药品有限公司 作为atp-结合盒转运蛋白调节剂用于治疗囊性纤维化的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物及相关化合物
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
LT2029173T (lt) 2006-06-26 2016-11-10 Macrogenics, Inc. Fc riib specifiniai antikūnai ir jų panaudojimo būdai
WO2010045633A2 (en) * 2008-10-17 2010-04-22 National Jewish Health Measurement and analysis of leukotrienes
WO2010075380A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
WO2010120935A1 (en) 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
CN103819459B (zh) 2009-06-11 2017-05-17 艾伯维巴哈马有限公司 抗病毒化合物
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8420655B2 (en) 2009-12-04 2013-04-16 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
BR112013001217B1 (pt) 2010-07-20 2019-11-19 Vestaron Corp composto, composição inseticida contendo o mesmo, e, método para controlar insetos
EP2632915B1 (en) 2010-10-29 2015-08-12 Boehringer Ingelheim International GmbH Benzimidazole inhibitors of leukotriene production
WO2012061169A1 (en) 2010-11-01 2012-05-10 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
TWI826525B (zh) 2018-09-18 2023-12-21 美商拓臻股份有限公司 用於治療特定白血病之化合物
CN110054558B (zh) * 2019-05-16 2022-03-25 海门瑞一医药科技有限公司 一种1-三氟甲基环丙烷-1-甲酸的制备方法
CN112441983B (zh) * 2019-08-29 2023-09-15 山东福长药业有限公司 一种基于苯并咪唑取代的硝基苯的化合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3017610A (en) * 1957-03-15 1962-01-16 Curtiss Wright Corp Electronic data file processor
US4939133A (en) * 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
LU86258A1 (fr) * 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US4744026A (en) * 1986-04-11 1988-05-10 American Telephone And Telegraph Company, At&T Bell Laboratories Methods and apparatus for efficient resource allocation
IT1232252B (it) * 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
EP0428939B1 (de) * 1989-11-21 1996-01-17 Bayer Ag Cumarinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und Thiazolyl-essigsäurederivate als Zwischenprodukte
DE69113162T2 (de) * 1990-08-02 1996-03-14 Hoffmann La Roche Antiallergische Mischung.
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
ES2102036T3 (es) 1992-06-15 1997-07-16 Celltech Therapeutics Ltd Derivados con grupo fenilo trisustituido utilizados como inhibidores selectivos de la fosfodiesterasa iv.
US5521813A (en) * 1993-01-15 1996-05-28 Strategic Weather Services System and method for the advanced prediction of weather impact on managerial planning applications
US5496826A (en) * 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
JP3223090B2 (ja) * 1994-12-27 2001-10-29 三井化学株式会社 フェニルベンズイミダゾール誘導体
US5821258A (en) 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
RU2084451C1 (ru) * 1995-10-17 1997-07-20 Акционерное общество закрытого типа "Алмазный Центр" Способ получения 2-фенилбензимидазола
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6988076B2 (en) * 1997-05-21 2006-01-17 Khimetrics, Inc. Strategic planning and optimization system
CA2332999A1 (en) * 1998-05-22 1999-12-02 Avanir Pharmaceuticals Compounds having ige affecting properties
US6910017B1 (en) * 1999-03-05 2005-06-21 Profitlogic, Inc. Inventory and price decision support
US6405175B1 (en) * 1999-07-27 2002-06-11 David Way Ng Shopping scouts web site for rewarding customer referrals on product and price information with rewards scaled by the number of shoppers using the information
US6546387B1 (en) * 1999-11-15 2003-04-08 Transcom Software Inc. Computer network information management system and method using intelligent software agents
US20020042739A1 (en) * 2000-03-13 2002-04-11 Kannan Srinivasan Method and system for creating and administering internet marketing promotions
US20020023001A1 (en) * 2000-07-11 2002-02-21 Mcfarlin James A. Method and apparatus for online creation and sale of custom local store marketing materials
US7072848B2 (en) * 2000-11-15 2006-07-04 Manugistics, Inc. Promotion pricing system and method
US20020198794A1 (en) * 2001-06-21 2002-12-26 Williams Edward P. Inventory management system for determining suggested part stocking levels for a vehicle dealer

Also Published As

Publication number Publication date
HUP0102128A3 (en) 2002-05-28
WO1999061013A3 (en) 2000-04-06
BR9910640A (pt) 2001-10-30
HUP0102550A3 (en) 2002-11-28
AU4094299A (en) 1999-12-13
PL345219A1 (en) 2001-12-03
KR100591652B1 (ko) 2006-06-26
DE69924607D1 (de) 2005-05-12
HUP0102128A2 (hu) 2002-03-28
CN1219510C (zh) 2005-09-21
EP1077700A1 (en) 2001-02-28
ZA200007754B (en) 2001-08-16
CN1721411A (zh) 2006-01-18
NO20005889D0 (no) 2000-11-21
IL139828A0 (en) 2002-02-10
AU4197899A (en) 1999-12-13
AU4312099A (en) 1999-12-13
PL345560A1 (en) 2001-12-17
ZA200007752B (en) 2001-12-05
IL139826A0 (en) 2002-02-10
AU754943B2 (en) 2002-11-28
CA2332999A1 (en) 1999-12-02
BR9910642A (pt) 2001-10-09
NZ508413A (en) 2003-08-29
HUP0101894A2 (hu) 2002-02-28
MXPA00011470A (es) 2002-10-17
KR20010030179A (ko) 2001-04-16
ZA200007753B (en) 2001-07-18
CZ20004351A3 (cs) 2001-10-17
JP2002516274A (ja) 2002-06-04
WO1999061013A2 (en) 1999-12-02
HUP0101894A3 (en) 2002-07-29
JP2002516276A (ja) 2002-06-04
US6451829B2 (en) 2002-09-17
CZ20004350A3 (cs) 2002-02-13
ES2241285T3 (es) 2005-10-16
JP2002516277A (ja) 2002-06-04
CA2332989A1 (en) 1999-12-02
US20020010343A1 (en) 2002-01-24
DE69924607T2 (de) 2006-02-02
CN1311675A (zh) 2001-09-05
MXPA00011422A (es) 2002-12-13
NZ508416A (en) 2004-01-30
CA2332985A1 (en) 1999-12-02
EP1079830A1 (en) 2001-03-07
US6271390B1 (en) 2001-08-07
HUP0102550A2 (hu) 2001-10-28
EP1077695A2 (en) 2001-02-28
CN1317965A (zh) 2001-10-17
NO20005888L (no) 2001-01-22
WO1999061020A1 (en) 1999-12-02
UA67775C2 (uk) 2004-07-15
AU754562B2 (en) 2002-11-21
ATE292465T1 (de) 2005-04-15
EP1077700B1 (en) 2005-04-06
NO20005889L (no) 2001-01-22
RU2236220C2 (ru) 2004-09-20
CN1311679A (zh) 2001-09-05
NO20005887L (no) 2001-01-19
PL345952A1 (en) 2002-01-14
RU2236221C2 (ru) 2004-09-20
NO20005887D0 (no) 2000-11-21
UA67774C2 (uk) 2004-07-15
MXPA00011467A (es) 2002-10-17
NO20005888D0 (no) 2000-11-21
WO1999061019A1 (en) 1999-12-02
IL139827A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
BR9910641A (pt) Derivados de benzimidazol como moduladores de ige
BR0208010A (pt) Composto de benzimidazol para modulação de ige e inibição de proliferação celular
PT1153024E (pt) 2-amino-6-anilino-purinas e sua utilizacao como medicamentos
BR0314223A (pt) Compostos fenil-indol para modular ige e inibir proliferação celular
BRPI0408388A (pt) compostos de benzopirano úteis no tratamento de patologias inflamatórias
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
UY26130A1 (es) Compuestos para tratar la obesidad
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
BRPI0409097A (pt) derivados de imidazol para tratamento de distúrbios alérgicos e hiperproliferativos
DE60307749D1 (de) Verwendung von Flavonoid-Derivaten zur Behandlung von atopischem Ekzem
ATE489361T1 (de) Derivate von alpha-phenylthiocarbon- und alpha- phenyloxycarbonsäuren, die für die behandlung von auf die aktivierung von ppar alpha ansprechende krankheiten geeignet sind
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
BR9608245A (pt) Derivados de piperazino como antagonistas de neurocinina
BR0113147A (pt) Proteìnas e peptìdeos do estresse e métodos de uso dos mesmos
ATE375152T1 (de) Behandlung von gastrointestinalen erkrankungen mit n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2- amine
ATE406868T1 (de) Verwendung einer zusammensetzung mit vitamin k1- oxid oder einem derivat daraus zur behandlung und/oder vorbeugung von hautverletzungen bei säugern
ATE299151T1 (de) Sequenzvarianten des menschlichen beta-1- adrenozeptorgens und ihre verwendung
SE9901273D0 (sv) Novel compounds
FI972673A7 (fi) 4,4-(disubstituoitu)sykloheksan-1-oli-monomeereja ja vastaavia yhdiste itä
ATE359088T1 (de) Verwendung von interleukin-18 zur behandlung von uv-assoziierten hautkrankheiten
DOP2005000261A (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4,5-d] pirrimidin-2-ona 3,5-disustituida y 3,5,7-trisustituida y profarmacos de los mismo
TR200301800A2 (tr) Bir farmasötik terkip.
EP1555020A3 (en) Benzimidazole derivatives as modulators IgE
DE112004000945D2 (de) Testsystem für die Findung von Wirkstoffen gegen prioneninduzierte Erkrankungen und Wirkstoffe zur Verhütung und zur Behandlung dieser Erkrankungen
HN2003000166A (es) Amidas de acidos 2-heteroarilcarboxilicos

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI